Guanfacine in Children with Tourette’s Disorder or Chronic Tic Disorders

Principal Investigator: Barbara Coffey, MD, MS

Co-Investigators: Lawrence Scahill, MSN PhD; Tanya Murphy, MD

Sponsor: Shire Pharmaceuticals

Overview: This is a double blind pilot study designed to determine whether extended release guanfacine (an FDA-approved medication for high blood pressure and ADHD) is safe and beneficial in the treatment of children and adolescents with TD or Chronic Tic Disorder.

Inclusion Criteria

  • Diagnosis of TD or chronic motor or vocal tic disorder
  • Child must be unmedicated (or on stable medication treatment for OCD, anxiety, or depressive disorder for at least 8 weeks)
  • Children on stable doses of an SSRI will be allowed to enter the trial

Exclusion Criteria

  • Current primary diagnosis requiring pharmacotherapy
  • Past or current history of abuse or diagnosis of Post-Traumatic Stress Disorder (PTSD)
  • Significant medical condition that would be incompatible with the study drug, e.g., children with a history of cardiac arrhythmia
  • Prior history of hypersensitivity to guanfacine or prior failed treatment with an adequate trial of guanfacine in the last 2 years
  • Use of another psychotropic or a stimulant medication for tics
  • Participation in behavioral therapy for tics
  • Current participation in another research project involving medication therapy

Based on this information, if you think that you or your child might be a good candidate for this study and would like to be contacted by the study team to find out more, please complete this form.

(Currently closed to enrollment)